Bioscience, Biotechnology and Biochemistry 2012
In vivo anti-tumor activity of a new doxorubicin conjugate via α-linolenic acid.
Články mohou překládat pouze registrovaní uživatelé
Přihlášení Registrace
Odkaz je uložen do schránky
Klíčová slova
Abstraktní
The conventional chemotherapy agent, doxorubicin, is of limited clinical use because of its systemic toxicity toward normal healthy tissue. A new doxorubicin conjugate with α-linolenic acid showed good anti-tumor activity with lower toxicity than free doxorubicin and exhibited an active tumor-targeting profile due to the introduction of α-linolenic acid which might be an effective tumor-targeting moiety for the modification of chemotherapeutics.